Whether GLP1-RAs induce a similar magnitude of weight loss in patients with breast cancer, particularly those concurrently receiving endocrine therapy (ET), is unknown
IQVIA EMEA Thought Leadership analysis Once the existing supply-demand gap has been resolved, we expect the obesity market will begin to exhibit more orthodox dynamics, driven by choice and competitive strategies seeking differentiation that is anchored on addressing specific unmet needs in discrete patient sub-populations
The pipeline is full, and everyone's treating this like an unqualified win for obesity medicine
Setting realistic goals, tracking progress, celebrating small victories, and surrounding yourself with supportive people can help keep you motivated
Glucagon-like peptide-1 stimulates human insulin promoter activity in part through cAMP-responsive elements that lie upstream and downstream of the transcription start site